**Dial-Assist integrates personalized** patient guidance, Al-driven behavioral analytics, and proactive clinical support to rapidly deliver better patient outcomes, significant healthcare cost reductions, improved provider margins, and compelling investor returns.

> Dean Feener, Founder Precision Dialysis Solutions LLC

> > precisiondialysis.com

### **Home Dialysis is Tough**



**Overwhelming Complexity** – Roughly 80 detailed steps per session creates a challenge for consistent protocol execution.



**Fear and Anxiety** – Mistakes and procedural burdens are leading reasons patients avoid or abandon home dialysis.



**Costly Consequences** – Poor adherence triggers complications, hospitalizations, penalties, and rising healthcare costs.



**Data Blind Spot** – No reliable data currently exists on patient adherence to home procedures.

# Why It Matters To Me

When my soon-to-be 80-year-old dad, Max, wanted to dialyze at his house, the clinic planned to send him home equipped only with a step-by-step binder. I knew immediately that wouldn't be enough for him to succeed. He needed something far better.

So, I created **Dial-Assist** as a personal mission, a tool designed specifically to help him safely and confidently manage his hemodialysis sessions. Then I built **ClarityAl** and **Clara**, giving me real-time insight into how he was doing session-to-session, so we could proactively address any issues.

Seeing the dramatic improvement **Dial-Assist** made in his life, I quickly realized how valuable this solution could be for countless other patients facing similar challenges.

Five months later, he's thriving...no avoidable hospital readmissions, a remarkable improvement in confidence and quality of life, and best of all...he's now approved for a transplant!



### What I Did About It

#### Dial-Assist:

App with personalized, voice-guided dialysis steps using patient-specific images and videos to enhance recollection and increase patient confidence.

#### ClarityAl:

Advanced analytics quickly identify changes in patient adherence, enabling proactive notification and pre-critical intervention. ML for improved predictive modelling.

#### Clara:

Conversational chat-based assistant that delivers real-time, actionable insights, real-time on-demand graphs and charts, directly to nurses, improving care responsiveness.



# Market Opportunity

Total U.S. Dialysis Market: 500,000 patients

**Current Home Dialysis Adoption:** ~15% (75,000 patients), projected to grow rapidly due to regulatory and economic incentives.

**Government and Insurers Incentives:** Strong economic drive toward home dialysis (~\$34,000 annual savings per patient transitioned).

**Provider Needs:** Clear demand for solutions improving patient adherence and reducing complications, directly impacting margins and provider economics.

# **Competitive Landscape**


Feature / Capability	Fresenius / Davita (NxStage System One)	Fresenius (NxStage VersiHD)	Baxter (Amia with Sharesource)	Dial-Assist
Digital Guidance	×	🛕 (Machine set-up)	🛕 (Machine-use/PD)	
Patient-Specific Media	×	×	×	
Personalized Voice Guidance	×	×	🛆 (Machine-use)	
Adaptive Behavioral Analytics	×	×	🛆 (Machine-use)	(Adherence, Confidence)
Real-Time Clinician Insights	🛆 (Machine-data focused)	🛆 (Machine-data focused)	🛆 (Machine-data focused)	🗹 (Behavior-focused)
Session-Specific Dialyzer Data Integration				X (Future Integration)

**Our Unique Advantage:** 

- Patient-Specific Engagement (Dial-Assist): Proven approach using personalized media (patient's own images, equipment, environment).
- Al-Driven Adaptive Analytics (ClarityAl): Unique capability to identify subtle behavioral deviations early, ensuring safer, more proactive care.
- Conversational Clinical Interface (Clara): Provides real-time, actionable insights and information directly to nursing staff.

### Dial-Assist doesn't just do things better—it addresses critical gaps that current major providers haven't yet effectively tackled.

### **Why This Can Succeed**





Riyadh

Neil

•

Keith

Mark



#### Founder (Personally Invested):

- Dean Feener
- Chief Information Officer, The ALS Association
- Passionately founded Dial-Assist to solve real-world dialysis challenges for patients, starting with his father.

#### Strategic Advisors:

- Dr. Riyadh Alrubaye Practicing Nephrologist (Clinical & Dialysis Expertise)
- Dr. Neil Thaker Epidemiologist & Healthcare Policy Expert (Market & Regulatory Insights)
- Dr. Keith Gary Health-Tech Commercialization (Innovation & VC Network)
- Mark Fetner VP Key Accounts, Operations (Sales & Enterprise Growth)

### **The Team**

# **Business Model**



#### Primary Revenue Streams (B2B Licensing):

- Patient Subscription: \$100 per patient/month (\$1,200 annually)
- Clinic Subscription: \$2,500 per clinic/month (\$30,000 annually)

#### **Clear Adoption Incentives for Providers:**

• **Improved Adherence:** Directly reduces costly hospitalizations and complications, significantly enhancing provider margins.



- Avoidance of Penalties (ESRD QIP): Better adherence directly translates into fewer penalties and greater incentive-based payments under CMS quality programs.
- Home Dialysis Financial Incentives: Dial-Assist aligns providers with existing government and insurer incentives designed to shift patients successfully to home dialysis, capturing substantial per-patient savings (~\$34,000/year).



#### Why Providers Will be Interested:

• Dial-Assist directly impacts providers' financial and operational performance, incentivizing rapid adoption and long-term retention.

# **Financial Projections (5-Year Conservative Growth Model)**

Year	Home Dialysis Market Growth	Patients (Cumulative)	Clinics (Cumulative @100 patients each)	Patient Revenue (\$1,200/yr)	Clinic Revenue (\$30,000/yr)	Total Annual Revenue
1	+0.5%	2,500	25	\$3.0M	\$750K	\$3.75M
2	+1.0%	7,500	75	\$9.0M	\$2.25M	\$11.25M
3	+1.0%	12,500	125	\$15.0M	\$3.75M	\$18.75M
4	+1.5%	20,000	200	\$24.0M	\$6.0M	\$30.0M
5	+2.0%	30,000	300	\$36.0M	\$9.0M	\$45.0M

# What it Takes to Get There

#### Seed Funding: \$1.5M

Target Pre-Money Valuation: \$12-\$15M

**Allocation of Funds:** 

- Product Development & Enhancements (40%)
- Enhance Dial-Assist, ClarityAI, and Clara platforms for scale and regulatory compliance.
- Clinical Validation & Pilot Programs (30%)
- Execute targeted clinical pilots, validate outcomes with real-world data, and secure provider and insurer partnerships.
- Market Entry & Growth Initiatives (30%)
- Rapid market penetration through strategic partnerships, sales, marketing, and initial clinic onboarding.

#### Milestones this Funding Unlocks:

- Robust clinical evidence demonstrating clear market advantage.
- Initial revenue generation and proven provider adoption.
- Accelerated path toward scalable market leadership.

### **Contact and Next Steps**

#### **Dean Feener**

Founder, Precision Dialysis Solutions LLC dean.feener@precisiondialysis.com 404-416-0601 precisiondialysis.com

**Dialysis done right. Every time.**